Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Top Cited Papers
- 24 May 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (7), 895-903
- https://doi.org/10.1016/s1470-2045(17)30380-7
Abstract
No abstract availableFunding Information
- National Institute of Health (grant RO1CA208403 [EBG])
This publication has 29 references indexed in Scilit:
- Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?Cancer Immunology Research, 2014
- Radiation Therapy to Convert the Tumor Into an In Situ VaccineInternational Journal of Radiation Oncology*Biology*Physics, 2012
- Immunologic Privilege in the Central Nervous System and the Blood–Brain BarrierJournal of Cerebral Blood Flow & Metabolism, 2012
- Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell ActivationThe Journal of Immunology, 2012
- From Vaccines to Memory and BackImmunity, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation TherapyClinical Cancer Research, 2008
- Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loadingApoptosis, 2006
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyThe Journal of Experimental Medicine, 2006
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993